trols was within Hardy-Weinberg equilibrium. Odds ratio (OD) and their 95% confidence intervals were calculated to evaluate effects of different genotypes. We found a difference in the frequency of A/G alleles between the total amount of patients studied and controls which comes close to statistical significance ( 2 = 3.440; P = 0.063). The genotype distributions differed significantly in patients with AD compared to the controls ( 2 = 8.68; P = 0.013). The frequency of individuals who carried two copies of the Val allele was significantly increased in patients than in controls ( 2 = 6.202; P = 0.013, odds ratio: 1.994, 95% CI 1.15-3.46), suggesting that homozygosity for the Val allele confers an increased risk for AD.
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In order to examine the possible interaction between AD and APOE, we genotyped the 130 AD patients and we found 65 carrying the ⑀4 allele of APOE gene. There was no significant difference in the distribution of allele frequencies between the two groups ( 2 = 0.090, df = 1, P = 0.76) ( Table 1) , and we concluded that possible effects of Val on susceptibility to AD might be independent from the APOE genotype. These data are in agreement with a recent observation of association of another BDNF gene polymorphism (C270T in the 5ЈUTR) to late onset AD in the Japanese population. 9 Further studies are needed to confirm the relationship of two polymorphisms including a possible linkage disequilibrium.
In conclusion these results make the BDNF an important candidate gene for susceptibility of AD and might provide a baseline to rationalize the use of neurotrophins as possible therapeutic agents in specific human neurodegenerative diseases. 2 This receptor is implicated in the mechanism of action of atypical antipsychotic drugs that have a lower propensity to induce TD. Our positive findings were for the silent T102C polymorphism in the coding region and the A-1438G polymorphism in the promoter, which were in complete linkage disequilibrium in our sample. Patients with TD had a significant excess of 102C and −1438G alleles and of 102CC and −1438GG genotypes compared to patients without TD and normal control subjects. Patients carrying the 102CC and −1438GG genotypes had significantly higher scores on the sub-scales of the Abnormal Involuntary Movements Scale (AIMS) that measure dyskinetic trunk movements and degree of incapacitation.
Age
In the same issue of Molecular Psychiatry, Basile et al, 3 to whom we had communicated our unpublished findings, reported no allelic or genotypic association of the same polymorphisms in HTR2A with TD. Their patients carrying 102CC and −1438GG genotypes did not have higher AIMS total scores than patients homozygous for the wild-type allele. AIMS sub-scale scores were not reported. This disparity contrasts with similar findings of the two groups in the same patient samples in regard to association of the dopamine D3 receptor gene (DRD3) with TD. 4, 5 Among the demographic and clinical factors that have been associated with individual susceptibility to TD, age is the most consistently reported. In a prospective study, Jeste et al 6 found the cumulative incidence of TD in patients who initiated treatment with antipsychotic drugs after the age of 45, to be 60% after 3 years. In other studies too, aging appears to be the most predominant patient-related risk factor for TD. 7 We hypothesized that there may be an interaction between genes that predispose to TD and age whereby the effect of such genes may be expressed to a greater extent in older patients. Such an effect could explain the disparity between our findings 2 and those of Basile et al 3 in regard to the association of HTR2A with TD. The mean Molecular Psychiatry (±SD) age of our subjects was 52.2 ± 11.8 years while that of the Basile et al 3 sample was 33.2 ± 9.1. To test this hypothesis, we analyzed data from our HTR2A study 2 and from our studies in which we found an association of TD with a ser9gly polymorphism in DRD3 4 and with a cys23ser polymorphism in the serotonin 2C receptor gene (HTR2C). 8 All patients genotyped in our laboratory for these studies were analyzed, including subjects who were excluded from our published reports where the TD and non-TD groups were matched for age. There were a total of 147 subjects in the analysis. Their median age was 48 years (range 22-87) and on this basis they were divided into two groups (Young, Յ48, n = 73; Old, Ͼ48 years, n = 74). The mean (±SD) age of the Young group was 37.1 ± 7.7 years and of the Old group, 59.7 ± 7.7. There was no significant difference between the groups in gender or ethnic (Ashkenazi vs non-Ashkenazi Jews) distribution, average antipsychotic dose in chlorpromazine units at the time of evaluation nor frequency of current or past cigarette smoking. The Old group had a significantly later onset of antipsychotic treatment (28.2 ± 10.1 vs 21.5 ± 6.6 years, P Ͻ 0.0001) and a substantially longer period of exposure to antipsychotic drugs (28.8 ± 10.4 years vs 15.7 ± 8.8 years, P Ͻ 0.0001). The total AIMS scores of the Old group were significantly higher (7.1 ± 6.9 vs 3.0 ± 4.2, P Ͻ 0.0001) as were their scores on all the AIMS sub-scales. While age significantly influenced AIMS scores, there was no difference between males and females over the sample as a whole nor within age groups.
We performed a series of analyses of variance (ANOVA) in which the grouping variables were age group (Old or Young) and genotype for each of the three genes examined. The dependent variable was the AIMS total score. The mean ± standard error (SE) scores of the Young and Old patients grouped according to genotype are shown in Figure 1 . The upper panel shows the results for DRD3. ANOVA revealed a significant effect of age group (F = 10.5; df 1,130; P = 0.002) and DRD3 genotype (F = 4.2; df 2,130; P = 0.01). There was no significant interaction suggesting no differential effect of DRD3 on AIMS scores in Young vs Old patients. For the analysis of HTR2C (middle panel), male patients hemizygous for the cys or ser allele were considered homozygotes. The results showed a significant effect of age group (F = 23.3; df 1,130; P Ͻ 0.0001) and HTR2C genotype (F = 4.5; df 2, 130; P = 0.01). There was a significant interaction (F = 5.5; df 2,130; P = 0.004) reflecting an increased effect of HTR2C genotype in the older patients. For HTR2A (lower panel), the effect of age group (F = 10.0; df 1, 141; P = 0.001) and genotype (F = 4.0; df 2, 141; P = 0.01) and the interaction (F = 3.1; df 2, 141; P = 0.04) were again significant. To control for the substantial difference between the Old and Young groups in years of exposure to antipsychotic drugs, we repeated the analyses adding this variable as a covariate. Both the HTR2C (F = 5.16; df 2, 122; P = 0.0007) and HTR2A (F = 3.35; df 2, 132; P = 0.03) age groupgenotype interactions remained significant.
These findings support our hypothesis that the effect of certain genes on susceptibility to abnormal involuntary movements, which are the hallmark of TD, may be age-related. This was not true of DRD3 which, intriguingly, was found to be associated with TD by our group 4 and by Basile et al 5 and is a widely although not universally replicated genetic association with TD. [9] [10] [11] On the other hand, there was a significant age effect of HTR2A for which there was a disparity between our findings 2 and those of Basile et al. 3 As noted, the sample examined by Basile et al 3 was two decades younger, on average, than our sample. There is considerable evidence from post-mortem and neuroimaging studies that brain serotonin receptor density, particularly 5-HT2A receptor density, is reduced with age (reviewed in Cidis Meltzer et al 12 ). We found that the prolactin response to fenfluramine challenge, which is mediated by 5-HT2A/2C receptors, is blunted with age in healthy human subjects. 13 This suggests a possible mechanism for the age-related genetic effects on abnormal involuntary movements that we observed. Genetically based variations in receptor structure might become functionally relevant at an older age when receptor reserve is reduced for reasons related to the aging process. Another consideration is whether age-related changes in drug metabolism might play a role. This is unlikely because the two principal Molecular Psychiatry CYP450 isoforms that contribute to the disposition of classical antipsychotics (CYP2D6 and CYP1A2) have not been found to display a significant change in catalytic activity with age. 14, 15 The findings reported here suggest that in genetic association studies of antipsychotic drug adverse effects, such as TD, as well as pharmacogenetic studies in general, it is advisable to take into account a possible interaction between age and the candidate genes examined. 
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